[HTML][HTML] Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
V Ratziu, M Hompesch, M Petitjean… - Journal of …, 2024 - journal-of-hepatology.eu
The worldwide prevalence of non-alcoholic steatohepatitis (NASH) is increasing, causing a
significant medical burden, but no approved therapeutics are currently available. NASH drug …
significant medical burden, but no approved therapeutics are currently available. NASH drug …
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
V Ratziu, M Hompesch, M Petitjean, C Serdjebi… - Journal of …, 2023 - Elsevier
Non-alcoholic steatohepatitis (NASH) prevalence is increasing worldwide, causing a
significant medical burden, but no approved therapeutics are currently available. NASH drug …
significant medical burden, but no approved therapeutics are currently available. NASH drug …